Table 4 Monofactorial analysis of liver inflammation improvement
Factor | I Improved n (%) | Not improved n (%) | P | Unadjusted OR (95%CI) |
|---|---|---|---|---|
Treatment course of bicyclol (weeks) | 0.001 | 6.750 (2.300, 19.811) | ||
≥ 48 | 21 (70.00) | 9 (30.00) | ||
< 48 | 10 (25.00) | 30 (75.00) | ||
Age (years) | 0.211 | 2.639 (0.577, 12.064) | ||
≥ 50 | 5 (62.50) | 3 (37.50) | ||
< 50 | 24 (38.71) | 38 (61.29) | ||
Sex | 0.176 | 2.816 (0.705, 6.777) | ||
Female | 9 (56.25) | 7 (43.75) | ||
Male | 20 (37.04) | 34 (62.96) | ||
ALT (U/L) | 0.024 | 0.301 (0.107, 0.851) | ||
≥ 40 | 15 (31.91) | 32 (68.09) | ||
< 40 | 14 (60.87) | 9 (39.13) | ||
HBeAg | 0.184 | 1.923 (0.733, 5.043) | ||
Negative | 16 (50.00) | 16 (50.00) | ||
Positive | 13 (34.21) | 25 (65.79) | ||
HBV-DNA | 0.341 | 0.532 (0.146, 1.948) | ||
≥ 105 IU/mL | 23 (38.98) | 36 (61.02) | ||
< 105 IU/mL | 6 (54.55) | 5 (45.45) |